

Friday, 2nd February 2024

Time	Programme
08:30 - 09 : 15	Registration & Welcome Coffee

DISCOVERY AND INNOVATION TRACK Exploring innovations for Next-generation Cell and Gene Therapies Chairperson: Dr. Navin Khattry, ACTREC, TMC & Dr. Jyoti Anand Kode, ACTREC, Tata Memorial Centre .

Time	Title	Speaker
9:15 - 9:40	Tailored Gene Therapies Targeting Sickle Cell Anaemia	Dr. Akshay Sharma, St. Jude Children's Research Hospital, USA
9:40 - 10:05	Development of effective Pre-clinical animal models to predict outcomes in Human Trials	Dr. Wayne A. Marasco Harvard Medical School, USA
10:05-10:30	Harnessing Gene Therapy for Hemophilia and the Progress in India	Dr. Alok Srivastava Christian Medical College, Vellore, India

10:30 - 10:35

Q & A

Fire Side Panel Discussion Accelerating Innovation-A Roadmap for India Moderated by-Dr. Akrasubhra Ghosh, Narayan Nethralaya Eye Hospital

Time	Speaker	Speaker
	Dr. Rahul Purwar IIT Bombay, ImmunoACT, Mumbai, India	Dr. Raghu Padinjat National Centre for Biological Sciences (NCBS), Bangalore, India
10:35-11:05	Dr. Sivaprakash Ramalingam - Institute of Genomics and Integrative Biology (CSIR), Delhi India	Dr. Shashwati Basak Intas Pharmaceuticals, Ahmedabad, India
	Dr. Alok Srivastava Christian Medical College, Vellore, India	
11:05 - 11:20	Coffee Break	



3rd

SACT 2024

SCIENTIFIC

AGENDA

11:20 - 11:45	INAUGURATION CEREMONY		
	Opening Remarks	Dr. Albeena Nisar, Organizing Secretary- SACT, ACTREC, TM	
	Welcome Address	Dr. Navin Khattry, Deputy Director, CRC, ACTREC, TMC	
	Address by the Chairman of Scientific Committee	Dr. (Surg Cdr) Gaurav Narula, Chairman of Scientific Committee-SA	
11:20 - 11:45	Remarks	Dr. Prasanna Venkataraman, Deputy Director, CRI, Mumb	
11.20 - 11.40	Address by the Chief Guest	Dr. Jitendra Kumar, MD, DBT- BIRAC, New Delhi, India	
	Vote of Thanks Dr. Albeena Nisar		
	Lighting of Lamp & Inauguration		
	Special Address: The Concept of Innovation and Orchestration: "Translating Therapies from Bench to Bedside"	Dr. Khalid Shah, Harvard Medical School, USA	
Chairpersons: Dr. Nirali S	^r Process Optimization & Analytics For Faster Approval hah, NCI & Dr (Lt Col)Pawan Gupta, Stempeutics		
Time	Title	Speaker	
	Novel Manufacturing Process: CAR-T cell expansion platforms yield distinct T cell differentiation statesDr. Steven Highfill National Cancer Institute, USA		
11:45 - 12:10			
11:45 - 12:10 12:10 - 12:35		National Cancer Institute, USA	
	yield distinct T cell differentiation states	National Cancer Institute, USA Mr. Srinidhi Deshpande	
12:10 - 12:35 12:35 - 12:40 Fire Side Panel Discussion Planning Better for Faster	yield distinct T cell differentiation states Buy vs Build Manufacturing- Autologous CAR T Thera Q & A	National Cancer Institute, USA Apy Mr. Srinidhi Deshpande	
12:10 - 12:35 12:35 - 12:40 Fire Side Panel Discussion Planning Better for Faster	yield distinct T cell differentiation states Buy vs Build Manufacturing- Autologous CAR T Thera Q & A on Approvals	National Cancer Institute, USA Mr. Srinidhi Deshpande	
12:10 - 12:35 12:35 - 12:40 Fire Side Panel Discussion Planning Better for Faster Moderated by - Dr. Uday	yield distinct T cell differentiation states Buy vs Build Manufacturing- Autologous CAR T Thera Q & A on Approvals Kumar Kolkundkar Stempeutics	National Cancer Institute, USA apy Mr. Srinidhi Deshpande Cytiva, CCRM, Canada	
12:10 - 12:35 12:35 - 12:40 Fire Side Panel Discussion Planning Better for Faster Moderated by - Dr. Uday	yield distinct T cell differentiation states Buy vs Build Manufacturing- Autologous CAR T Thera Q & A on Approvals Kumar Kolkundkar Stempeutics Dr. Raviraja N. S. Manipal Academy of Higher Education,	National Cancer Institute, USA apy Mr. Srinidhi Deshpande Cytiva, CCRM, Canada Speaker Dr. Atharva Karulkar	



40.40 40.00

	Showcase Presentation- Thermo Fisher Scientific	
Time	Tittle	Speaker
13:10-13:35	Cell and Gene Therapy Solutions: Recent technical innovations that facilitate manufacturing steps in the CAR-T cell workflow	Dr. Roland Leathers Senior Manager, Thermo Fisher Scientific
13:35 - 14:30	LUNCH & POSTER WALK	
	Cell therapy for Solid Tumors & Beyond Chinaswamy, Tata Memorial Hospital & Dr. Prasanna Venka	atraman, ACTREC
Time	Tittle	Speaker
14:30-14:55	Gene Edited and Engineered Tumor cells: A New Immunotherapeutic Approach for Cancer	Dr. Khalid Shah Harvard Medical School, USA
14:55 - 15:20	Cellular Immunotherapies for Virus-associated Cancers and Post-transplant Infectious Complications	Dr. Rajiv Khanna QIMR Berghofer Medical Research Institute, Australia
15:20 - 15:45	Next-generation CARs- Targeting Solid Tumours taking into consideration the Tumour Microenvironment	Dr. Avery Posey Perelman School of Medicine, University of Pennsylvania, L
15:45 - 15:50	Q & A	
Fire Side Panel Discuss i Breaking "Solid" Barriers	Q & A on	
Fire Side Panel Discuss i Breaking "Solid" Barriers	Q & A on to Cell/ Gene Therapy	Speaker
Fire Side Panel Discussi Breaking "Solid" Barriers Moderated by: Dr. Albeer	Q & A on to Cell/ Gene Therapy na Nisar, ACTREC, Tata Memorial Centre	
Fire Side Panel Discussi Breaking "Solid" Barriers Moderated by: Dr. Albeer	Q & A on to Cell/ Gene Therapy ha Nisar, ACTREC, Tata Memorial Centre Speaker Dr. Shailendra Upraity	Speaker Dr. Rajiv Khanna
Fire Side Panel Discussi Breaking "Solid" Barriers Moderated by: Dr. Albeen Time	Q & A on to Cell/ Gene Therapy na Nisar, ACTREC, Tata Memorial Centre Speaker Dr. Shailendra Upraity Aurigene Pharmaceutical Services Limited, Banglore, India Dr. Khalid Shah	Speaker Dr. Rajiv Khanna QIMR Berghofer Medical Research Institute, Australia Dr. Rajarshi Pal Eyestem Research, C-CAMP, Bengaluru, India Dr. Avery Posey
Fire Side Panel Discussi Breaking "Solid" Barriers Moderated by: Dr. Albeen Time	Q & A on to Cell/ Gene Therapy na Nisar, ACTREC, Tata Memorial Centre Speaker Dr. Shailendra Upraity Aurigene Pharmaceutical Services Limited, Banglore, India Dr. Khalid Shah Harvard Medical School, USA Dr. Vainav Patel	Speaker Dr. Rajiv Khanna QIMR Berghofer Medical Research Institute, Australia Dr. Rajarshi Pal Eyestem Research, C-CAMP, Bengaluru, India

Thormo Fisher Colontif

Chauseasa Duesentation



Regulatory TRACK

From First In Human to Speeding up to Clinical Trials

Chairpersons: Dr. Shripad D. Banavali, Tata Memorial Centre & Dr. Stephan Grupp, CHOP, USA

Time	Title	Speaker
16:50-17:15	Regulatory Advice to Guide the Development of the Next Wave of Cell Therapies	Dr. Peter Marks Director, Center for Biologics Evaluation & Research (CEBR) FE
	Regulatory Frameworks for Cell Therapies II) Pawan Kumar Gupta, Stempeutics Research Pvt Ltd, Bar	ngalore, India
Time	Speaker	Speaker
	Dr. Peter Marks Director, Centre for Biologics Evaluation & Research (CEBR) FDA, USA	Dr. Geeta Jotwani Senior Deputy Director General, ICMR New Delhi, India
17:15- 17:45	Dr. Subrata Sinha All India Institute of Medical Sciences (AIIMS), New Delhi, India	Dr. Rajiv Khanna QIMR Berghofer Medical Research Institute, Australia
	Dr. Yogendra Kumar Gupta AIIMS Bhopal, AIIMS Jammu,Medical Advisor at VaidyaRx,New Delhi, India.	Dr. Annu Uppal US Pharmacopeia, Hyderabad, India
Č ,	oportunities Track ture of Cell Therapy in India: The Trajectory of Future Invest dra Kumar, DBT BIRAC, New Delhi, India	ment.
Paving the way for the Fut	ture of Cell Therapy in India: The Trajectory of Future Invest	rment. Speaker
Paving the way for the Fut CHAIRPERSON: Dr. Jiten	ure of Cell Therapy in India: The Trajectory of Future Invest dra Kumar, DBT BIRAC, New Delhi, India	Speaker Dr. Anand Covindaluri
Paving the way for the Fut CHAIRPERSON: Dr. Jiten Time 17:45-18:10 Fire Side Panel Discussi Fire Side Leadership Pane Moderated by Dr. Anand	ture of Cell Therapy in India: The Trajectory of Future Invest dra Kumar, DBT BIRAC, New Delhi, India Title Catalyzing Investments in Cell & Gene therapy Industry ion el Discussion Govindaluri, Govin Capital, Singapore	Speaker Dr. Anand Govindaluri Govin Capital, Singapore
Paving the way for the Fut CHAIRPERSON: Dr. Jiten Time 17:45-18:10 Fire Side Panel Discussi Fire Side Leadership Pane	ture of Cell Therapy in India: The Trajectory of Future Invest dra Kumar, DBT BIRAC, New Delhi, India Title Catalyzing Investments in Cell & Gene therapy Industry ion el Discussion	Speaker , Dr. Anand Govindaluri



	Dr. Raj K Shirumalla National Biopharma Mission, BIRAC, New Delhi, India	Dr. Mohammad Atif Alam Centre for Cellular and Molecular Platforms, Bangalore, India
18:10-18:40	Dr. Dinesh Kundu East Ocyon Bio Private Limited Gurugram, India.	
19:00 Onwards	Gal	la Dinner
aturday, 3 [™] Februa	ary 2024 D AY 2	
Time		rogramme
08:30 - 9:00	Cof	fee/Breakfast
AR-T Cells for Hematoly ssion 1: airpersons:		
	MER, Chandigarh, India & Dr. Swaminathan Iyer, MD Anders	
. Pankaj Malhotra, PGIN Time 09:00-09:25		Speaker
Time	Title The Landscape of CD19-directed CAR T Therapies for	Speaker Dr. Hasmukh Jain

10:15-10:20	Q & A
10:20 - 10:35	Tea/ Coffee break



Session 2 - Paediatric ALL: The CAR-T Cell Role Model Chairpersons: Dr. Shripad D. Banavali, Tata Memorial Centre & Dr. Revathi Raj, Apollo Hospitals Cancer Centre Nandanam, Chennai, India

Time	Title	Speaker
10:35 - 10:50	Emily Whitehead- The Story that Sailed Triggered a Cell Therapy Revolution Emily Whitehead Foundation, USA	
10:50-11:15	Building Better CAR T Therapies - Reflections of emergent challenges over a decade of CAR T cell therapy	Dr. Stephan A. Grupp Children's Hospital of Philadelphia, USA
11:15-11:40	Replacing chemotherapy with immune therapy in children and young persons with ALL	Dr Ajay Vora University of Sheffield, UK
11:40-12:05	First in Canada CAR-T Cell Therapy- Building Low Cost and Equitable Treatment Capacity	Dr. Kevin Hay Terry Fox Laboratory, Canada

Fire Side Panel Discussion

Integrating CAR T- Cells into Treatment Algorithms in India- Paving The Road Ahead **Moderated by** Dr. Gaurav Narula, Tata Memorial Hospital, TMC

Time	Speaker		Speaker
	Dr. Akanksha Chichra Tata Memorial Centre, Mumbai, India	Dr.Sharat Dam Narayana Healt	odar h, Bangalore, India
12:05-12:35	Dr Bhausaheb Bagal Tata Memorial Hospital, Mumbai, India	Dr. Nirali Shah National Cance	
	Dr. Stephan A. Grupp Children's Hospital of Philadelphia, USA	Dr Ajay Vora University of Sh	neffield, UK
12:35 - 13:35	LUNCH & POSTER WALK		
owcase Presentation airperson: Dr. Manoj I	Mahimkar, ACTREC, Mumbai, India		
. Vikaramjit Kanwar, H	lomi Bhabha Cancer Hospital, Varanasi, India		L Contraction of the second
: Vikaramjit Kanwar, H 13:35 - 14:00	Key Learnings from the Scale-Up of Pivotal Trial	in DLBCL	Dr. Anna Wijatyk, Miltenyi Biomedicine



CLINICAL TRACK

Monitoring & Measuring: Maximising Clinical Outcome with CAR-T Cell Therapy **Chairpersons:** Dr. P.G. Subramanian, ACTREC and Dr. Reena Das, PGI Chandigarh

Time	Title	Speaker
14:25-14:50	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis	Dr. Gaurav Chatterjee ACTREC, Mumbai, India
14:50 - 15:15	Third Party Virus Specific T-Cells Post Allogenic Transplant	Dr. Nishant Jindal, ACTREC, Mumbai, India
15:15 - 15:40	Off the shelf CAR-T approaches for Lymphoma	Dr. Swaminathan lyer MD Anderson Cancer Center, USA

15:45 - 15:55	TEA BREAK

15:55 - 16:15 Oral Poster Presentation

Fire Side Panel Discussion All Tools in One Box Moderated by Dr. Chetan Dhamne, ACTREC, TMC

Time	Title	Speaker
16:15 - 16:45	Dr. Pankaj Malhotra PGIMER, Chandigarh, India	Dr. Nikhil Patkar Tata Memorial Centre, Mumbai, INDIA
	Dr. Kevin Hay Terry Fox Laboratory, Canada	Dr. Sameer Bakhshi All India Institute of Medical Sciences, New Delhi, INDIA
	Dr. Gaurav Chatterjee ACTREC, Mumbai, India	Dr. Carlos Fernandez de Larrea University of Barcelona, Barcelona, Spain



3rd

SACT 2024

SCIENTIFIC

AGENDA

COMMERCIALIZATION TRACK

The trajectory of future investment and easy patient accessibility mode

Fire Side Panel Discussion

Think Tank-Industry

Moderated by Dr. Anand Govindaluri, Govin Capital, Singapore

Time	Speaker	Speaker
16:45 - 17:15	Dr. Murali Ramachandra Aurigene Oncology, Bangalore, India.	Dr. Mahesh Bhalgat Syngene International Limited, Bangalore, India
	Mr. Shirish Arya ImmunoACT, Mumbai, India	Dr. Samir Kulkarni Institute Of Chemical Technology, Mumbai, India.
	Dr. Jeevan Ghosalkar - Cipla Limited, Mumbai, India	

PATIENT ADVOCACY TRACK

Equity, Access & Affordability of Cell Therapies

Time	Title	Speaker	
17:15 - 17:45	Fire Side Panel Discussion with leading Oncologists, Patient Solution Focused Agencies and Patient Advocate groups	<i>Moderated by</i> Ms. Shalini Jatia Impact Foundation	
17:45 - 18:15	Valedictory		
	Closing Remarks		